Intracranial low-grade gliomas in adults: 30-Year experience with long-term follow-up at Mayo Clinic

Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Neuro-Oncology (Impact Factor: 5.56). 12/2008; 11(4):437-45. DOI: 10.1215/15228517-2008-102
Source: PubMed


The purpose of this study was to evaluate long-term survival in patients with nonpilocytic low-grade gliomas (LGGs). Records of 314 adult patients with nonpilocytic LGGs diagnosed between 1960 and 1992 at the Mayo Clinic, Rochester, Minnesota, were retrospectively reviewed. The Kaplan-Meier method estimated progression-free survival (PFS) and overall survival (OS). Median age at diagnosis was 36 years. Median follow-up was 13.6 years. Operative pathology revealed pure astrocytoma in 181 patients (58%), oligoastrocytoma in 99 (31%), and oligodendroglioma in 34 (11%). Gross total resection (GTR) was achieved in 41 patients (13%), radical subtotal resection (rSTR) in 33 (11%), subtotal resection in 130 (41%), and biopsy only in 110 (35%). Median OS was 6.9 years (range, 1 month-38.5 years). Adverse prognostic factors for OS identified by multivariate analysis were tumor size 5 cm or larger, pure astrocytoma histology, Kernohan grade 2, undergoing less than rSTR, and presentation with sensory motor symptoms. Statistically significant adverse prognostic factors for PFS by multivariate analysis were only tumor size 5 cm or larger and undergoing less than rSTR. In patients who underwent less than rSTR, radiotherapy (RT) was associated with improved OS and PFS. A substantial proportion of patients have a good long-term prognosis after GTR and rSTR, with nearly half of patients free of recurrence 10 years after diagnosis. Postoperative RT was associated with improved OS and PFS and is recommended for patients after subtotal resection or biopsy.

Download full-text


Available from: Paul D Brown, May 19, 2014
  • Source
    • "Reporting on the EOR has not been standardized. Several publications have reported the surgeon's intraoperative impression of completeness of the resection without radiological verification [8]–[12]. Others have reported the percentage of patients with ‘gross total tumor removal’ using radiological verification, but with varying definitions, such as “no radiological residual glioma tissue”, “less than 1 cm rim”, and “resection of at least 90% of the preoperative glioma volume” [13]–[15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intraoperative brain stimulation mapping reduces permanent postoperative deficits and extends tumor removal in resective surgery for glioma patients. Successful functional mapping is assumed to depend on the surgical team's expertise. In this study, glioma resection results are quantified and compared using a novel approach, so-called resection probability maps (RPM), exemplified by a surgical team comparison, here with long and short experience in mapping. Adult patients with glioma were included by two centers with two and fifteen years of mapping experience. Resective surgery was targeted at non-enhanced MRI extension and was limited by functional boundaries. Neurological outcome was compared. To compare resection results, we applied RPMs to quantify and compare the resection probability throughout the brain at 1 mm resolution. Considerations for spatial dependence and multiple comparisons were taken into account. The senior surgical team contributed 56, and the junior team 52 patients. The patient cohorts were comparable in age, preoperative tumor volume, lateralization, and lobe localization. Neurological outcome was similar between teams. The resection probability on the RPMs was very similar, with none (0%) of 703,967 voxels in left-sided tumors being differentially resected, and 124 (0.02%) of 644,153 voxels in right-sided tumors. RPMs provide a quantitative volumetric method to compare resection results, which we present as standard for quality assessment of resective glioma surgery because brain location bias is avoided. Stimulation mapping is a robust surgical technique, because the neurological outcome and functional-based resection results using stimulation mapping are independent of surgical experience, supporting wider implementation.
    Full-text · Article · Sep 2013 · PLoS ONE
  • Source
    • "However, the favorable results could possibly be explained by selection of patients with well-established favorable prognostic factors such as younger age (mean: 29 years), almost perfect clinical condition (KPS mean: 93.45), and small tumors (mean: 13.9 cc). These patients might probably do equally well with external beam radiotherapy alone or in combination with surgery (8, 24, 27). The five-year survival rates of brachytherapy using SBT method have been reported to be between 54.6% to 97% (14, 22, 23, 30, 31), which is in line with our findings. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of low-grade astrocytoma (WHO grade II) (LGA II) remains a challenge. There is limited information regarding the long-term effects of stereotactic brachytherapy (SBT) (temporary (125)Iodine seeds) on patients with LGA II. The purpose of this study was to evaluate disease control and survival after stereotactic brachytherapy in patients with circumscribed and relatively small size tumors. A retrospective review of 29 patients, treated between 1991 and 2011, was conducted to evaluate survival, complications, and local disease control after stereotactic brachytherapy. They belonged to a larger group of 48 cases with low-grade gliomas, treated with stereotactic brachytherapy. The demographic and clinical characteristics in patients including age, sex, and survival time were extracted from records. Thirteen patients were male and 16 were female, with the median age of 29 years (range, 2.5 - 64 years). The median follow-up was 95 (range, 6 - 240) months. Based on Pignatti classification, 10 patients were at low- and 19 patients at high-risk. The median overall as well as progression-free survivals for patients were 135 months (95% confidence interval: 76 - 194) and 96 months (95% confidence interval: 1 - 199), respectively. Five- and 10-year progression-free survivals were 41.4 % and 34.5 %, respectively, and the 5- and 10-year overall survivals were 65.5 % and 44.8%, respectively. Progression-free survival was not significantly higher in smaller size tumors (P = 0.224), nor for spherical versus non-spherical tumors (P = 0.307). There was no treatment-related morbidity after stereotactic brachytherapy, and no radiogenic complications occurred during the follow-up period. Mortality due to tumor progression occurred in 4 patients (14%), and 11 patients were alive at the last follow-up. The stereotactic brachytherapy for patients with circumscribed and relatively small size tumors appears to be a safe, feasible, and minimally-invasive treatment.
    Full-text · Article · Jan 2013
  • Source
    • "However, when we stratified HGG patients and primary GBM patients by BSP expression, separately, we found that the PFS and OS of HGG patients and primary GBM patients expressing high levels of BSP were considerably reduced compared with those expressing low levels of BSP, suggesting that BSP is an independent predictor of the therapeutic outcome of HGG patients. LGG patients have a better prognosis than HGG patients and have a median survival of almost 84 months [22]. In the current study, most LGG patients were alive and progression free at the last follow-up, so we cannot accurately predict the prognostic value of BSP for OS in LGG patients right now, which may require future studies with a follow-up period of sufficient duration that allows the analysis of such endpoints as recurrence or death. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the expression and prognostic value of bone sialoprotein (BSP) in glioma patients. We determined the expression of BSP using real-time RT-PCR and immunohistochemistry in tissue microarrays containing 15 normal brain and 270 glioma samples. Cumulative survival was calculated by the Kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate analyses were performed by the stepwise forward Cox regression model. Both BSP mRNA and protein levels were significantly elevated in high-grade glioma tissues compared with those of normal brain and low-grade glioma tissues, and BSP expression positively correlated with tumor grade (P<0.001). Univariate and multivariate analysis showed high BSP expression was an independent prognostic factor for a shorter progression-free survival (PFS) and overall survival (OS) in both grade III and grade IV glioma patients [hazard ratio (HR) = 2.549 and 3.154 for grade III glioma, and HR = 1.637 and 1.574 for grade IV glioma, respectively]. Patients with low BSP expression had a significantly longer median OS and PFS than those with high BSP expression. Small extent of resection and lineage of astrocyte served as independent risk factors of both shorter PFS and OS in grade III glioma patients; GBM patients without O(6)-methylguanine (O(6)-meG) DNA methyltransferase (MGMT) methylation and Karnofsky performance score (KPS) less than 70 points were related to poor prognosis. Lack of radiotherapy related to shorter OS but not affect PFS in both grade III and grade IV glioma patients. High BSP expression occurs in a significant subset of high-grade glioma patients and predicts a poorer outcome. The study identifies a potentially useful molecular marker for the categorization and targeted therapy of gliomas.
    Full-text · Article · Oct 2012 · PLoS ONE
Show more